Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma

BACKGROUND: Purpose: The combination of a mammalian target of rapamycin inhibitor and lenalidomide showed enhanced preclinical cytotoxicity. We conducted a phase 1 study in advanced solid tumour patients to assess safety, efficacy and pharmacodynamic (PD) outcomes. METHODS: We employed a 3+3 dose es...

Descripción completa

Detalles Bibliográficos
Autores principales: Harvey, R. Donald, Carthon, Bradley C., Lewis, Colleen, Hossain, Mohammad S., Zhang, Chao, Chen, Zhengjia, Harris, Wayne B., Alese, Olatunji B., Shaib, Walid, Bilen, Mehmet A., Lawson, David H., Wu, Christina, Steuer, Conor E., El-Rayes, Bassel F., Khuri, Fadlo R., Lonial, Sagar, Waller, Edmund K., Ramalingam, Suresh S., Owonikoko, Taofeek K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553949/
https://www.ncbi.nlm.nih.gov/pubmed/32704173
http://dx.doi.org/10.1038/s41416-020-0988-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553949/
https://www.ncbi.nlm.nih.gov/pubmed/32704173
http://dx.doi.org/10.1038/s41416-020-0988-2

Ejemplares similares